Rare pathogenic structural variants show potential to enhance prostate cancer germline testing for African men

Keyphrases

• Structural Variation 100%
• Prostate Cancer 100%
• African Men 100%
• Germline Testing 100%
• Structural Variants 100%
• Germline Genes 100%
• European Patients 33%
• BARD1 33%
• Human Disease 33%
• DNA Repair 33%
• Functional Genes 33%
• Human Prostate 33%
• Prostate Cancer Patients 33%
• Major Contributor 33%
• Rare Variants 33%
• Tumor Suppressor 33%
• Loss Function 33%
• Standard of Care 33%
• Lethality 33%
• Specific Loss Power 33%
• African Ancestry 33%
• Tumourigenesis 33%
• Pathogenicity 33%
• MLH1 33%
• Mega 33%
• Genomic Data 33%
• Test Guideline 33%
• FOXP1 33%
• Care Recommendations 33%
• Gene Candidates 33%
• Pathogenicity Prediction 33%
• Testing Standards 33%
• Therapeutic Testing 33%
• African Diaspora 33%
• Germline 33%
• Whole Genome Data 33%
• Lack of Representation 33%
• Familial Testing 33%

Biochemistry, Genetics and Molecular Biology

• Germline 100%
• Germ Cell 100%
• BARD1 25%
• Candidate Gene 25%
• DNA Repair 25%
• Tumor Suppressor Protein 25%
• Carcinogenesis 25%
• MLH1 25%
• Gene Function 25%
• FOXP1 25%
• Genomics 25%
• Rare Variant 25%